Brett Spear

Dr. Brett Spear

Microbiology, Immunology & Molecular Genetics, College of Medicine, University of Kentucky, Lexington, KY, USA

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1995 in Nature Genetics
Verified
Journal Article
Closed access
DBDaniel L. Burgess
Daniel L. Burgess
DKDavid C. Kohrman
David C. Kohrman
JGJames Galt
James Galt
NPNicholas W. Plummer
Nicholas W. Plummer
JJJulie M. Jones
Julie M. Jones
MMMiriam H. Meisler
Miriam H. Meisler

18 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RGRoberto Gedaly
Roberto Gedaly
RGRoberto Galuppo
Roberto Galuppo
MDMichael F. Daily
Michael F. Daily
MSMalay Shah
Malay Shah
EMErin Maynard
Erin Maynard
BSBrett Spear
Brett Spear
Activation of the Wnt/β-catenin pathway has been observed in at least 1/3 of hepatocellular carcinomas (HCC), and a significant number of these have mutations in the β-catenin gene. Therefore, effective inhibition of this pathway could provide a novel method to treat HCC. The purposed of this study was to determine whether FH535, which was previously shown to block the β-catenin pathway, could inhibit β-catenin activation of target genes and inhibit proliferation of Liver Cancer Stem Cells (LCSC) and HCC cell lines. Using β-catenin responsive reporter genes, our data indicates that FH535 can inhibit target gene activation by endogenous and exogenously expressed β-catenin, including the constitutively active form of β-catenin that contains a Serine37Alanine mutation. Our data also indicate that proliferation of LCSC and HCC lines is inhibited by FH535 in a dose-dependent manner, and that this correlates with a decrease in the percentage of cells in S phase. Finally, we also show that expression of two well-characterized targets of β-catenin, Cyclin D1 and Survivin, is reduced by FH535. Taken together, this data indicates that FH535 has potential therapeutic value in treatment of liver cancer. Importantly, these results suggest that this therapy may be effective at several levels by targeting both HCC and LCSC.

30 December 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SPSudhir Perincheri
Sudhir Perincheri
RDR. W. Cameron Dingle
R. W. Cameron Dingle
MPMartha L. Peterson
Martha L. Peterson
BSBrett Spear
Brett Spear
The α-fetoprotein ( AFP ) and H19 genes are transcribed at high levels in the mammalian fetal liver but are rapidly repressed postnatally. This repression in the liver is controlled, at least in part, by the Afr1 gene. Afr1 was defined >25 years ago when BALB/cJ mice were found to have 5- to 20-fold higher adult serum AFP levels compared with all other mouse strains; subsequent studies showed that this elevation was due to higher Afp expression in the liver. H19 , which has become a model for genomic imprinting, was identified initially in a screen for Afr1 -regulated genes. The BALB/cJ allele ( Afr1 b ) is recessive to the wild-type allele ( Afr1 a ), consistent with the idea that Afr1 functions as a repressor. By high-resolution mapping, we identified a gene that maps to the Afr1 interval on chromosome 15 and encodes a putative zinc fingers and homeoboxes (ZHX) protein. In BALB/cJ mice, this gene contains a murine endogenous retrovirus within its first intron and produces predominantly an aberrant transcript that no longer encodes a functional protein. Liver-specific overexpression of a Zhx2 transgene restores wild-type H19 repression on a BALB/cJ background, confirming that this gene is responsible for hereditary persistence of Afp and H19 in the livers of BALB/cJ mice. Thus we have identified a genetically defined transcription factor that is involved in developmental gene silencing in mammals. We present a model to explain the liver-specific phenotype in BALB/cJ mice, even though Afr1 is a ubiquitously expressed gene.

1 March 2002 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
JTJob C. Tharappel
Job C. Tharappel
ELEun Y. Lee
Eun Y. Lee
LRLarry W. Robertson
Larry W. Robertson
BSBrett Spear
Brett Spear
HGHoward P. Glauert
Howard P. Glauert

1 June 2012 in Gastroenterology
Verified
Journal Article
Open access
PDF file
XYXuetian Yue
Xuetian Yue
ZZZhenyu Zhang
Zhenyu Zhang
XLXiaohong Liang
Xiaohong Liang
LGLifen Gao
Lifen Gao
XZXiaoning Zhang
Xiaoning Zhang
CMChunhong Ma
Chunhong Ma
Background & Aims Zinc-fingers and homeoboxes 2 (ZHX2) represses transcription of several genes associated with liver cancer. However, little is known about the role of ZHX2 in the development of hepatocellular carcinoma (HCC). We investigated the mechanisms by which ZHX2 might affect proliferation of HCC cells. Methods We overexpressed and knocked down ZHX2 in HCC cells and analyzed the effects on proliferation, colony formation, and the cell cycle. We also analyzed the effects of ZHX2 overexpression in growth of HepG2.2.15 tumor xenografts in nude mice. Chromatin immunoprecipitation and luciferase reporter assays were used to measure binding of ZHX2 target promoters. Levels of ZHX2 in HCC samples were evaluated by immunohistochemistry. Results ZHX2 overexpression significantly reduced proliferation of HCC cells and growth of tumor xenografts in mice; it led to G1 arrest and reduced levels of Cyclins A and E in HCC cell lines. ZHX2 bound to promoter regions of CCNA2 (which encodes Cyclin A) and CCNE1 (which encodes Cyclin E) and inhibited their transcription. Knockdown of Cyclin A or Cyclin E reduced the increased proliferation mediated by ZHX2 knockdown. Nuclear localization of ZHX2 was required for it to inhibit proliferation of HCC cells in culture and in mice. Nuclear localization of ZHX2 was reduced in human HCC samples, even in small tumors (diameter, <5 cm), compared with adjacent nontumor tissues. Moreover, reduced nuclear levels of ZHX2 correlated with reduced survival times of patients, high levels of tumor microvascularization, and hepatocyte proliferation. Conclusions ZHX2 inhibits HCC cell proliferation by preventing expression of Cyclins A and E, and reduces growth of xenograft tumors in mice. Loss of nuclear ZHX2 might be an early step in the development of HCC.

29 October 2007 in Hepatology
Verified
Journal Article
Open access
PDF file
LMLorri A. Morford
Lorri A. Morford
CDChristina Davis
Christina Davis
LJLin Jin
Lin Jin
ADAneta Dobierzewska
Aneta Dobierzewska
MPMartha L. Peterson
Martha L. Peterson
BSBrett Spear
Brett Spear
The Glypican 3 ( Gpc3 ) gene is expressed abundantly in the fetal liver, is inactive in the normal adult liver, and is frequently reactivated in hepatocellular carcinoma (HCC). This reactivation in HCC has led to considerable interest in Gpc3 as a diagnostic tumor marker and its possible role in tumorigenesis. Despite this interest, the basis for Gpc3 regulation is poorly understood. On the basis of the similarities between Gpc3 and alpha - fetoprotein expression in the liver, we reasoned that common factors might regulate these 2 genes. Here we identify zinc fingers and homeoboxes 2 (Zhx2) as a regulator of Gpc3 . Mouse strain–specific differences in adult liver Gpc3 messenger RNA levels and transgenic mouse studies indicate that Zhx2 represses Gpc3 expression in the adult liver. We also demonstrate that Gpc3 is activated in the regenerating liver following a carbon tetrachloride treatment and that the level of Gpc3 induction is controlled by alpha-fetoprotein regulator 2 (Afr2). Conclusion: We show that Zhx2 acts as a repressor of Gpc3 in the adult liver, and this raises the interesting possibility that Zhx2 might also be involved in Gpc3 reactivation in HCC. We also show that Gpc3 is activated in the regenerating liver in an Afr2-dependent manner. Zhx2 and Afr2 represent the first known regulators of Gpc3 .